Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zastaprazan in NERD
NCT07160790Phase 3Not yet recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of zastaprazan in Non-erosive Gastroesophageal Reflux Disease (NERD) (3 arms), sponsored by Onconic Therapeutics Inc. Primary endpoint: The proportion of days with no heartburn at 4 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
zastaprazan
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on NCT07160790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160790.